 The wholesale cost of romiplostim if administered weekly is currently estimated at US $55,250 per year.On August 22, 2008, the FDA approved romiplostim as a long-term treatment for chronic ITP in adults who have not responded to other treatments, such as corticosteroids, intravenous immunoglobulin, Rho(D) immune globulin or splenectomy.Romiplostim treatment is generally administered at weekly intervals via subcutaneous injection.